Thymic peptide hormones: Basic properties and clinical applications in cancer

Critical Reviews in Oncology and Hematology

Volumn 3, Issue 4, 1985, Pages 309-376

  Schulof, Richard S ^a   Davis, Stephen ^b,c  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Serono Laboratories Randolph ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BCG VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ESTROGEN; ETOPOSIDE; FLUOROURACIL; HUMORAL THYMUS FACTOR; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PEPTIDE HORMONE; PLACEBO; PROCARBAZINE; SEMUSTINE; THYMOPOIETIN; THYMOSIN ALPHA1; THYMOSIN BETA4; THYMOSIN FRACTION 5; THYMOSTIMULIN; THYMULIN; THYMUS FACTOR 10; THYMUS HORMONE; VINCRISTINE;

ADVERSE DRUG REACTION; AUTOIMMUNE DISEASE; BIOCHEMISTRY; CANCER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FEVER; HELPER CELL; HUMAN; IMMUNE DEFICIENCY; INJECTION PAIN; NOMENCLATURE; PHARMACOKINETICS; PHARMACOLOGY; REVIEW; SUPPRESSOR CELL; THERAPY; THYMOPOIETIN I 125; THYMOSIN ALPHA11; THYMOSIN ALPHA5; THYMOSIN ALPHA7; THYMOSIN BETA1; THYMOSIN BETA10; THYMOSIN BETA3; THYMOSIN BETA8; THYMOSIN BETA9; THYMUS; URTICARIA;

AMINO ACID SEQUENCE; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, SURFACE; AUTOIMMUNE DISEASES; BIOLOGICAL ASSAY; CELL DIFFERENTIATION; EPITHELIUM; HUMAN; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; TERMINOLOGY; THYMECTOMY; THYMIC FACTOR, CIRCULATING; THYMOPOIETINS; THYMOSIN; THYMUS EXTRACTS; THYMUS GLAND; THYMUS HORMONES;

EID: 0022382799     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(85)80035-4     Document Type: Article

References (322)

1. Role of thymic hormones in T cell differentiation
2. Thymic hormones
3. Biochemical and biological properties of THF in animal and human models
4. The thymus gland: experimental and clinical studies of its role in the development and expression of immune functions
5. Thymosins and other hormone-like factors of the thymus gland
6. Immunological function of the thymus
7. Role of the thymus in development of the immune response
8. The role of the thymus in development of immunologic capacity in rabbits and mice
9. Prevention of wasting in mice thymectomized at birth and their subsequent rejection of allogeneic leukemia cells
10. Evidence for function of thymic tissue in diffusion chambers implanted in neonatally thymectomized mice. Preliminary report
11. Studies of thymic function
12. The effects of thymus and other lymphoid organs enclosed in millipore chambers on neonatally thymectomized mice
13. Carcinogen-induced tumors of the thymus: restoration of neonatally thymectomized mice with thymomas in cell-impermeable chambers
14. Evidence for a humoral thymus factor responsible for the maturation of immunological faculty
15. Reserches sur la symbiose lymphoepitheliale au niveau du thymus de mannifere
16. Influence of thymosin on immunological competence of lymphoid cells from thymectomized mice
17. Reduction in the incidence of wasting disease in neonatally thymectomized CBA/W mice by the injection of thymosin
18. Influence of thymosin on cell-mediated and humoral immune responses in normal and in immunologically deficient mice
19. 3H thymidine
20. Delayed Effect of Thymectomy in Adult Life on Immunological Competence
21. Effect of thymectomy in adult mice on immunological responsiveness
22. Origins of immunoreactive lymphocytes in rats
23. The influence of adult thymectomy on immunological competence as measured by the mixed lymphocyte reaction
24. Antigen-induced depression of DNA synthesis in mouse spleen
25. Regulation of the immune response by subclasses of T lymphocytes. II. The effect of adult thymectomy upon humoral and cellular responses in mice
26. Adult thymectomy prevention of the appearance of suppressor T cells which depress contact sensitivity to picryl chloride and reversal of adult thymectomy effect by thymus extract
27. Suppressor cell regulation of immune response to tumors: Abrogation by adult thymectomy
28. Regulation of contact sensitivity to DNFB in the mouse. Effects of adult thymectomy and thymic factor
29. Functional heterogeneity among the T-derived lymphocytes of the mouse
30. Population dynamics of T lymphocytes, renewal rate and expansion in the peripheral lymphoid organs
31. Studies on thymus products. II. Demonstration and characteristics of a circulating thymic hormone
32. Pine structure of the epithelial reticular cells of the medulla of the thymus in the golden hamster
33. The ultrastructure of the normal human thymus: a study of 36 cases
34. Age-related changes in localization of thymosin in the human thymus
35. The ultrastructure of epithelial reticular cells
36. Ultrastructure of the chick thymus
37. Peptide and amine producing endocrine-like cells in the chicken thymus
38. Ultrastructure studies on erythropoiesis in the avian thymus. I. Description of cell types
39. An electron microscopic study of thymic corpuscles in the guinea pig and the mouse
40. Ultrastructure of the fetal thymus in the golden hamster
41. The Thymus—Experimental and Clinical Studies
42. The fine structure of the thymus of the fetal and neonatal monkey (macaca mulatta)
43. Ultrastructure studies on cells containing secretory granules in the early embryonic thymus
44. Ultrastructure of human fetal thymus
45. Fine structural evidence for hormone secretion by the human thymus
46. Ultrastructure of the human thymus, thymic tumors, and myasthenia gravis
47. The Ultrastructure of Thymic Epithelial Reticular Cells
48. Demonstration of abnormalities of expression of thymic epithelial surface antigens in severe cellular immunodeficiency diseases
49. 5
50. 5 by pancreatic islet cells
51. THE NEW VIEWS AS TO THE MORPHOLOGY OF THE THYMUS GLAND AND THEIR BEARING ON THE PROBLEM OF THE FUNCTION OF THE THYMUS
52. Studies on thymus products. III. Epithelial origin of the serum thymic factor
53. Thymic hormone containing cells. II. Evolution of cells containing the serum thymic factor (FTS or thymulin) in normal and autoimmune mice, as revealed by anti-FTS monoclonal antibodies. Relationship with Ia bearing cells
54. Thymic dependency of rosette-forming cells. Evidence of a circulating thymic hormone
55. Myasthenia gravis, thymectomy and serum thymic hormone activity
56. Age, thymic involution and circulating thymic hormone activity
57. Circulating thymic hormone activity in patients with primary and secondary immunodeficiency diseases
58. Evidence for a serum factor produced by the human thymus
59. Enhancement of in vivo incorporation of labeled precursors into DNA and total protein of mouse lymph nodes after administration of thymic extracts
60. Effects of the thymus lymphocytopoietic factor
61. Preparation, assay and partial purification of a thymic lymphocytopoietic factor (thymosin)
62. The thymus gland: experimental and clinical studies of its role in the development and expression of immune functions
63. Purification and properties of bovine thymosin
64. 1
65. Influence of thymosin on cell-mediated and humoral immune responses to normal and immunologically deficient mice
66. 1 from calf thymus
67. Presence of thymosin-like factors in human thymic epithelium conditioned medium
68. 1 in myasthenia gravis
69. Monoclonal antibody against human T cell leukemia virus p19 defines a human thymic epithelial antigen acquired during ontogeny
70. Purification of thymus RNA coding for a 16000 dalton polypeptide containing the thymosin alpha 1 sequence
71. 1 from thymosin fraction 5 of different species by high-performance liquid chromatography
72. 1 in normal and thymectomized mice
73. Evidence for a circadian thythm of thymosin alpha-1 in humans
74. Thymopoietin-like substance in human skin
75. 1
76. 1
77. 1
78. 1 in Escherichia coli through expression of a chemically synthesized gene
79. Structure and function of thymosin factors
80. 1 isolated from calf thymosin fraction 5
81. The complete animo acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells
82. 2 and COOH-terminal amino acid sequence of nuclear protein A24
83. Amino-terminal sequence identity of ubiquitin and the nonhistone component of nuclear protein A24
84. Glucose exchange and catalysis by two crystalline hexokinase glucose complexes
85. 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymolyte populations
86. 4
87. 4 by peritoneal macrophages and adherent spleen cells
88. Two new peptides isolated from calf thymus homologous to thymosin B4
89. Thymin: a thymic polypeptide causing the neuromuscular block of myastenia gravis
90. Polypeptides regulating lymphocyte differentiation
91. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin
92. Induction of T cell differentiation in vitro by thymin, a purified polypeptide hormone of the thymus
93. Isolation of bovein thymin: a polypeptide hormone of the thymus
94. THE ISOLATION OF THYMOPOIETIN (THYMIN)
95. Complete amino acid sequences of bovine thymopoietine, I, II and III: closely homologous polypeptides
96. Synthesis of the nonatetracontapeptide corresponding to the sequence proposed for thymopoietin II.
97. Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination
98. What is a thymic hormone?
99. Radioimmunoassay for thymopoietin
100. Improved radioimmunoassay technique for measuring serum thymopoietin
101. Bioassay determinations of thymopoietin and thymic hormone levels in human plasma.
102. Increased reactivity of responding cells in mixed lymphocyte reaction by a thymic humoral factor
103. Immunological profile in sarcoidosis patients. The in vitro and in vivo effect of thymic humoral factor
104. Hormone-like activity of a thymus humoral factor on the incubation of immune competence in lymphoid cells
105. Isolation and partial chemical characterization of THF, a thymus hormone involved in immune maturation of lymphoid cells
106. Early Effect of Adult Thymectomy
107. Studies on thymus products. I. Modification of rosette-forming cells by thymic extracts determination of the target RFC subpopulation
108. Antigen recognition by T lymphocytes. II. Similar effects of azathioprine, ALS and antitheta serum on rosette-forming lymphocytes in normals and neonatally thymectomized mice
109. Structural study of circulating thymic factor, a peptide isolated from pig serum. II. Amino acid sequence
110. Structural study of circulating thymic factor: a peptide isolated from pig serum. I. Isolation and purication
111. The serum thymic factor and its synthesis
112. Synthesis of a proposed thymic factor
113. Contribution of zinc and other metals to the biological activity of the serum thymic factor (FTS)
114. Thymic hormone-contining cells
115. Characterization of facteur thymique serique (FTS) in the thymus
116. Generation of a monoclonal antibody against facteur thymique serique (FTS)
117. Radioimmunoassays for the thymic hormone serum thymic factor (FTS)
118. Thymectomy in the young pig: effects on the level of circulating thymic hormone
119. 1 using tert-butyloxycarbonylaminoacyl-4-(oxymethyl)phenylacetamidomethyl-resin
120. 1 C-terminal peptides in the azathioprine E-rosette inhibition assay
121. Selected phenotypic induction of null lymphocytes from mice with thymic and nonthymic agents
122. Thymic serum factor
123. Evaluation of serum thymic hormone and of circulating T cells in rheumatoid arthritis and in systemic lupus erythematosus
124. Cytoplasmic localization of FTS (facteur thymique sterique) in thymic epithelial cells. An immunoelectronmicroscopical study
125. Immunohistologic localization of facteur thymique serique' (FTS) in human thymic epithelium
126. Epithelial cell components immunoreact with anti-serum thymic factor (FTS) antibodies: possible association with intermediate-sized filaments
127. Characterization of facteur thymique serique (FTS) in the thymus. II. Direct demonstration of the presence of FTS in thymosin fraction V
128. Evidence of the presence in normal serum of a carrier of the serum factor (FTS)
129. Thymulin (FTS-Zn)
130. Thymic hormone-like restoration by human prealbumin of azathioprine sensitivity of spleen cells from thymectomized mice.
131. Neonatal thymus grafts. II. Cellular events
132. Thymic hormone containing cells. III. Evidence for a feed-back regulation of the secretion of the serum thymic factor (FTS) by thymic epithelial cells
133. Pharmacological and biological properties of a calf thymus extract (TP-1)
134. Thymus substitution and HTH, the homeostatic thymus hormone
135. LSH, a lymphocyte-stimulating hormone
136. Biologic activity of thymic protein extracts
137. Thymic factor in human sera demonstratable by a cyclic AMP assay
138. A thymus-dependent serum factor induces maturation of thymocytes as evaluated by a graft-versus-host reaction
139. Decreased serum thymic factor activity in asthmatic children
140. Structural requirement for the biological activity of serum thymic factor
141. Deficiency of autologous mixed lymphocyte reactions and serum thymic factor level in Down's syndrome
142. Evaluation of thymic hormone serum levels in health and disease
143. Thymic activity in severe combined immunodeficiency diseases
144. Circulating thymic hormone activity in congenital immunodeficiency
145. Low serum thymic hormone levels in patients with acquired immunodeficiency syndrome
146. Lymphocyte markers, serum thymic factor and IgE in IgA deficiency
147. Improvement of cellular immunity and IgA production in immunodeficient children after treatment with synthetic serum thymic factor (FTS)
148. Serum thymic hormone activity with systemic lupus erythematosus
149. Multivariate analysis of T cell functional defects and circulating serum factors in Hodgkin's disease
150. An inhibitor of thymic hormone activity in serum from patients with lymphoblastic leukemia
151. Plasma thymic hormone activity in patients with chronic mucocutaneous candidiasis
152. Thymoma with hypersecretion of thymic hormone
153. Circulating thymic factor, facteur thymique serique (FTS), in mycosis fungoides and sezarg syndrome
154. Keratin cytoskeletons in epithelial cells of internal organs
155. ‘Nude’, a new hairless gene with pleitrophic effects in the mouse
156. 1
157. Thymosin alpha 1 levels in children with primary cellular immunodeficiency and in adult with malignancy
158. Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunction
159. The evolutionary origins of hormones, neurotransmitters, and other extracellular chemical messengers
160. The thymus gland and reproduction: do thymic peptides influence the reproductive lifespan in females?
161. 1 levels associated with evidence of immune dysregulation in male homosexuals with a history of infectious diseases or Kaposi's sarcoma
162. Immunological characterization of homosexual males
163. 1 levels and helper-suppressor ratios in homosexual men
164. Immunologic studies of the acquired immune deficiency syndrome: relationship of immunodeficiency to extent of disease
165. 1 levels in hemophiliacs and their spouses
166. 1 levels in hemophilia A
167. Thymic epithelial injury in the acquired immune deficiency syndrome
168. Role of thymostimulin (TP-1) as an immunomodulatory in Hodgkin's disease
169. Suppressor cell responses in patients with rheumatoid arthritis: the effect of thymosin
170. Phase I trial of thymosin fraction V in advanced malignancies—preliminary NCOG report
171. 1 levels in patients with chronic progressive multiple sclerosis
172. 1 administration in man: a prototypic thymic hormone efficacy trial in patients with lung cancer
173. 1 administration in patients with lung cancer: preliminary results
174. Hormonal assays employing tissue receptors
175. Specific receptors for the serum thymic factor (FTS) in lymphoblastoid cultured cell line
176. Receptors for thymosin fraction 5 on rat thymic lymphocytes
177. 1 in patients with myasthenia gravis: effect of thymectomy
178. Thymosin-induced suppression of proliferative response of human lymphocytes to mitogen
179. Maturational effects of thymic hormones on human helper and suppressor T cells: effects of FTS (facteur thymique serique) and thymosin
180. Thymic hormone effect on human peripheral blood lymphocyte in vitro. III. Conditions for mixed lymphocyte-tumor culture assay
181. a-desacetyl thymosin
182. Thymosin increases T-cell growth-factor production by normal peripheral blood lymphocytes
183. Role of serum thymic factor (FTS) in the development of interleukin-2 producer lymphocytes
184. Differentiation of human bone marrow cells into T lymphocytes by in vitro incubation with thymic extracts
185. In vitro differentiation of human marrow cells into T lymphocytes by thymic extracts using the rosette technique
186. Early stages of human marrow lymphocyte differentiation: induction in vitro by thymopoietin and ubiquitin
187. Induction of differentiation in human marrow T-cell precursors by the synthetic serum factor, FTS
188. In vitro differentiation of human marrow T cell precursors by thymic factors in severe combined immunodeficiency
189. Differentiation of peripheral blood lymphocytes into cells bearing sheep erythrocyte receptors in vitro by human thymic extracts
190. The in vitro induction and differentiation of putative human stem cells by thymosin and agent that affect cyclic AMP
191. Characterization of thymosin-responsive peripheral blood null cells
192. Depletion of human T-lymphocyte antigens (HTLA antigens) on thymosin-inducible T-cell precursors
193. The effect of a human plasma thymic factor on human peripheral blood mononuclear cell subpopulations
194. Human post-thymic precursor cells in health and disease. VI. Effect of serum thymic factor on the response of cells from patients with systemic lupus erythematosus or mixed connective tissue disease in autologous mixed lymphocyte reaction
195. Autologous rosette-forming T cells as the responding cells in human autologous mixed-lymphocyte reaction
196. Activation of T cell rosettes in immunodeficient patients by thymosin
197. Severe combined immunodeficiency with cartilagehair hypoplasia: in vitro response to thymosin and attempted reconstitution
198. Experience with thymosin in primary immunodeficiency disease
199. Immunotherapy and immunopathologic studies in a patient with nucleoside phosphorylase deficiency
200. In Vivo and in Vitro Effects of Thymosin and Adenosine Deaminase on Adenosine-Deaminase-Deficient Lymphocytes
201. IN VITRO AND IN VIVO ENHANCEMENT OF MIXED LYMPHOCYTE CULTURE REACTIVITY BY THYMOSIN IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE
202. Thymosin therapy in the DiGeorge syndrome
203. Thymic hormones in primary immunodeficiency
204. Thymosin-induced increased in E-rosette-forming capacity of lymphocytes in patients with malignant neoplasms
205. Partial restoration by in vivo thymosin of E-rosettes and delayed-type-hypersenitivity reactions in immunodeficient cancer patients
206. The effect of thymosin on patients with disseminated malignancies
207. Thymosin reconstitution of T cell deficits in vitro in cancer patients
208. Effects of thymosin in vitro in cancer patients and correlation with clinical course after thymosin immunotherapy
209. Use of thymosin in the treatment of primary immunodeficiency diseases and cancer
210. Thymosin-inducible lymphocytes in the peripheral blood of patients with malignant melanoma
211. The importance of dose of thymosin for the in vitro induction of T lymphocytes from patients with solid tumors
212. Thymosin-inducible 'null' cells in atopic eczema
213. T-cell depletion and thymosin inducibility in asthmatic children
214. Effect of thymosin on T-lymphocyte functions in patients with acute thermal burns
215. Influenza: response of T cell lymphopenia to thymosin
216. In vitro thymosin effect on T-lymphocytes in alcoholic liver disease
217. Immunodeficiency in chronic uremia. Preliminary evidence for thymosin deficiency
218. In vitro restoration by thymosin of T lymphocytes from patient with lung tuberculosis
219. Effect of thymosin on T-lymphocyte rosette formation in children with Kwashiorkor
220. The in vitro effect of thymosin on T-lymphocyte rosette formation in rheumatic diseases
221. Infantile partial thymic deficiency: correction of some in vitro T-functions by THF
222. Immune deficiencies of T-system with possible T cell regulatory activity defect
223. Effect of thymic humoral factor on cellular immune functions of normal children and of pediatric patients with ataxia telangiectasia and Down's syndrome
224. In vitro effect of thymic humoral factor on human peripheral blood lymphocytes from normal and immunodeficient patients
225. Severe disseminated adenovirus infection successfully treated with a thymus humoral factor, THF
226. The in vitro effect of thymic hormonal factor and levamisole on peripheral blood lymphocytes in systemic lupus erythematosus patients
227. Effect of levamisole, thymic humoral factor and indomethacin on E-rosette formation in Hodgkin's disease
228. Response to thymopoietin pentapeptide in a patient with DiGeorge syndrome
229. The in vitro effect of the thymic factor thymopoietin on a subpopulation of lymphocytes from severely malnourished children
230. In vitro induction of monoclonal antibody-defined T cell markers in lymphocytes from immunodeficient children by synthetic serum thymic factor (FTS)
231. Immunological and clinical investigation of a bovine thymic extract. II. Therapeutical application in primary immunodeficiencies
232. Effects of thymic hormones on immunodeficiency
233. The in vitro effect of calf thymus extract (thymostimulin) on the immunologic parameters of patients with untreated Hodgkin's disease
234. The in vitro effect of a calf thymus extract (TP-1) on the peripheral blood lymphocytes of 66 melanoma patients
235. Thymic function in man
236. Thymosin-dependent T-lymphocyte response in inflammatory bowel disease
237. Comparison of the in vitro effects of thymopoietin pentapeptide and levamisole on pheripheral E-rosette-forming cells
238. Thymosin a, restores the depressed binding of autologous erythrocytes by T-cells from cancer patients
239. Preliminary clinical findings with TP-5 in the treatment of rheumatoid arthritis
240. Improvement of impaired leukocyte migration inhibition by thymosin in patients with head and neck squamous carcinoma
241. The effect of thymosin on human T cells from cancer patients
242. In vitro and in vivo studies of thymosin activity in cancer patients
243. Induction of suppressor T cells in systemic lupus erythematosus by thymosin and cultured thymic epithelium
244. Development of Systemic Lupus Erythematosus After Thymectomy for Myasthenia Gravis
245. Ability of thymosin to decrease in in vivo and in vitro suppressor cell activity in tumor bearing mice and cancer patients
246. Radiosensitive, thymic hormone-sensitive peripheral blood suppressor cell activity in cancer patients
247. Thymosin activity in patients with cellular immunodeficiency
248. Thymosin treatment of children with primary immunodeficiency disease
249. Thymosin treatment of DiGeorge syndrome
250. Hypoparathyroidism with T-cell deficiency and hypo immunoglobulinomia: response to thymosin therapy
251. Treatment of cell-mediated immunodeficiency with calf thymic hormone (TP-1)
252. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency
253. The role of THF, a thymic hormone, as a regulator of T-cell differentiation in humans
254. Therapy of viral disease in immunosuppressed patients with TP-1
255. Preliminary report: thymosin administration in autoimmune disorders
256. Immunokinetics of a Single Dose of Thymopoietin Pentapeptide
257. Partial restoration by in vivo thymosin of E-rosettes and delayed-type hypersensitivity reactions in immunodeficient cancer patients
258. Thymosin in patients with disseminated solid tumors: phase I and II results
259. Clinical trials with thymosin
260. Thymosin alpha 1: first clinical trial and comparison with thymosin fraction 5
261. Phase I trials of thymosin fraction 5 and thymosin
262. 1
263. Phase I trial using thymosin fraction V in renal cancer—NCOG report
264. Phase I trial of thymosin fraction 5 in cancer patients
265. Phase II trial of thymosin fraction 5 in advanced renal cancer
266. Evidence for a neuroendocrine-thymis axis mediated by thymosin polypeptides
267. Reduced gonadotropins in athymic mice: prevention by thymic transplantation
268. The hormonal basis of reproductive defects in athymic mice: diminished gonadotropin concentrations in prepubertal females
269. The thymus-adrenal connection: thymosin has corticotropin-releasing activity in primates
270. The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease
271. The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients
272. In vivo immunorestorative properties of thymostimulin (TS) in patients with Hodgkin's disease
273. Thymosin adjuvant therapy
274. Biologic modification of immunologic parameters in head and neck cancer patients with thymosin fraction V
275. Effect of thymosin and irradiation on immune modulation in head and neck and esophageal cancer patients
276. Immunosuppression and reconstitution with thymosin after radiation therapy
277. Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course
278. Enhancement of the immune system of chemotherapy-treated cancer patients by simultaneous treatment with thymic extract, TP-1
279. 1
280. 1 in patients with lung cancer
281. Thymosin fraction V and intensive combination chemotherapy
282. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy
283. Role of suppressor cells in depression of in vitro lymphoproliferative responses of lung cancer and breast cancer patients
284. Evidence for the appearance of non-specific suppressor cells in the blood after local radiation therapy
285. Sample size nomograms for interpreting negative clinical studies
286. Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results
287. Clinical and immunological evaluation of the use of thymosin plus BCG±DTIC in the adjuvant treatment of stage 3B melanoma
288. The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma
289. Active immunotherapy with BCG for recurrent malignant melanoma
290. BCG immunotherapy of malignant melanoma: summary of seven years experience
291. Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy
292. Clinical and immunological evaluation in non-resectable lung cancer patients treated with thymostimulin
293. Advanced lung cancer treated with combination chemotherapy with or without thymostimulin
294. Phase III study of thymosin fraction 5 in the treatment of metastatic renal cell carcinoma
295. The thymosins-preclinical and clinical studies with fraction V and alpha I
296. Effect of a thymic factor on T lymphocytes in B Cell chronic lymphocyte leukemia: in vitro and in vivo studies